Related Experiment Video
Updated: Apr 16, 2026
06:03
Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
9.9K
mRNA medicine for cardiovascular disease
Zhuoming Zhou1, Wei Chen1, Haojie Yu2,3
1Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nature Cardiovascular Research
|April 14, 2026
Summary
Messenger RNA (mRNA) therapeutics offer new hope for treating cardiovascular diseases (CVDs), the leading cause of death globally. Advances in mRNA technology, delivery systems, and related fields are paving the way for innovative CVD treatments.
Area of Science:
- Biotechnology and Pharmaceutical Sciences
- Cardiovascular Medicine
- RNA Therapeutics
Background:
- Cardiovascular disease (CVD) is the primary cause of global mortality, necessitating novel therapeutic strategies.
- Messenger RNA (mRNA) technology has demonstrated significant success, presenting new avenues for CVD treatment.
- Existing knowledge in mRNA therapeutics, cardiovascular pathophysiology, and nanotechnology fuels advancements in mRNA medicine.
Purpose of the Study:
- To provide a comprehensive overview of mRNA-based biotechnologies for cardiovascular diseases (CVDs).
- To summarize the preclinical and clinical applications of mRNA medicine in various CVDs.
- To discuss challenges and future directions for translating mRNA technology from research to clinical practice for CVDs.
Main Methods:
- Review of advancements in mRNA modifications and delivery platforms.
- Exploration of mRNA-encoded genomic and epigenomic editing techniques.
- Analysis of mRNA-based chimeric antigen receptors for immune cell engineering.
- Summary of preclinical and clinical studies on mRNA applications in hypercholesterolemia, atherosclerosis, ischemic cardiac injury, cardiac fibrosis, and cardiac amyloidosis.
Main Results:
- mRNA technology encompasses modifications, delivery systems, genomic/epigenomic editing, and CAR T-cell engineering for CVDs.
- Promising preclinical and clinical data exist for mRNA applications in hypercholesterolemia, atherosclerosis, ischemic cardiac injury, cardiac fibrosis, and cardiac amyloidosis.
- Several mRNA-based CVD therapies have progressed to clinical trials.
Conclusions:
- mRNA medicine holds significant promise for addressing a range of cardiovascular diseases.
- Continued research and development are crucial for overcoming challenges in mRNA technology translation.
- Future directions focus on optimizing mRNA therapies for effective bench-to-bedside application in CVDs.
Related Concept Videos
01:21Imaging Studies for Cardiovascular System IV: CMRI
555
Cardiovascular magnetic resonance imaging, or CMRI, is a non-invasive diagnostic test that employs a magnetic field and radiofrequency waves to create precise images of the heart and arteries. It provides comprehensive information about cardiac anatomy, function, perfusion, and tissue characterization without ionizing radiation.IndicationsCMRI diagnoses various heart conditions, including tissue damage from heart attacks, ischemic heart disease, myocarditis, aortic issues (tears, aneurysms,...
555
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
909
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
909
01:26Atherosclerosis III: Management
605
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
605
01:21Rheumatic Heart Disease III: Medical Management
523
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
523
01:25Mitral Regurgitation III: Medical Management
617
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
617
01:28Mitral Regurgitation IV: Nursing Management
555
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
555